Navigation Links
Publication on Pixantrone Preclinical Studies Demonstrates Reduced,Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and,Mitoxantrone

fludarabine and rituximab (F-R) in the treatment of patients who have received at least one prior treatment for NHL. The trial is expected to enroll 300 patients.

About Pixantrone

Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors and immunological disorders. It was developed to improve the activity and safety of the anthracycline family of anti-cancer agents. Anthracyclines have been shown to be very active clinically in a number of tumor types. However, they are usually associated with cumulative heart damage that prevents them from being used in a large proportion of patients. Pixantrone has been designed to reduce the potential for these severe cardiotoxicities, as well as to potentially increase activity and simplify administration compared to the currently marketed anthracyclines.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit http://www.cticseattle.com.

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general and with pixantrone in particular including, without limitation, the potential failure of pixantrone to have the same cardiotoxicity profile in humans as demonstrated in preclinical studies or to prove safe and effective for treatment of non-Hodgkin's lymphoma or other cancer, determinations by regulatory, patent and administrative governmental authorities,
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
2. DOR BioPharma Announces Publication Describing Results of Its Multivalent Botulinum Toxin Vaccine BT-VACC
3. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
4. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
5. Nuvelo Announces Publication of Phase 2 rNAPc2 Study Results in Journal of American College of Cardiology
6. Critical Therapeutics Announces the Publication of Data for ZyfloCR (Zileuton) Extended-Release Tablets in the Journal of Asthma
7. Nuvelo Announces Publication of Preclinical Study Results Demonstrating the Potential of NTB-A as a New Target for Leukemia and Lymphomas
8. Thallion Announces Publication of ECO-4601 Phase I/II Clinical Data at ASCO
9. Cytogen Reports Publication Validating the Utility of its Proprietary ProChart Database
10. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
11. Independent Publication Confirms Growing Therapeutic Challenge of T315I Mutation in Patients with CML, Notes ChemGenex
Post Your Comments:
(Date:12/24/2014)... , Dec. 23, 2014   Assurex Health, ... support to healthcare providers for behavioral health and ... secured $30 million in equity financing from new ... Drosos , President and Chief Executive Officer. ... and development of Assurex Health,s GeneSight ® ...
(Date:12/24/2014)... , Dec. 23, 2014 Tianyin ... company that specializes in patented biopharmaceutical, modernized traditional ... ingredients (API) today announced that the Company achieved ... Good Manufacturing Practice (GMP) certificate of TPI,s Qionglai ... Administration,s (CFDA). The public notice period is a ...
(Date:12/24/2014)...  Medical Science Liaisons play a large role in ... medical device industry and key stakeholders, the role of ... as the device industry relies on them to build ... benchmarking firm, Best Practices, LLC, one area where Medical ... by harnessing new technology to enable education. Online conferences ...
Breaking Medicine Technology:Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 2Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 3Assurex Health Secures $30 Million Financing Round to Continue Growth in Neuropsychiatric Pharmacogenomics 4TPI QLF Achieved Public Notice Status of GMP Certification 2TPI QLF Achieved Public Notice Status of GMP Certification 3Role of Medical Science Liaisons Evolving in Medical Device Sector 2
... 21, 2010 Reportlinker.com announces that a new ... Thai Self-monitoring of Blood Glucose ... http://www.reportlinker.com/p0350305/Thai-Self-monitoring-of-Blood-Glucose-SMBG-Devices-and-Strips-Market.html This Market Engineering ... dynamics of blood glucose monitoring device sales and ...
... 2010 The American Veterinary Medical Association (AVMA) has offered ... on a useful and effective induction agent, propofol. ... Schedule IV drug.  In a letter to the DEA today, ... this effective drug, which typically causes few side effects when ...
Cached Medicine Technology:AVMA Offers Important Guidance to DEA on New Controls for Induction Agent—Propofol 2
(Date:12/25/2014)... 2014 Product liability lawsuits filed in ... ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward in federal ... issued in the U.S. District Court, Northern District of ... open conference on January 7, 2015, at the Paul ... West Palm Beach, Florida. The Conference is scheduled to ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 Recently, iFitDress.com, the ... for women, has announced its new selection of black ... are on sale now; they are available at discounted prices, ... says, “The promotion will last for three weeks only. You ... market. Those who are interested in our new items can ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 The short film ... was created in honor of a true 9/11 hero, Welles ... film festivals including the 24 hours of Nuremberg International Short ... Bangladesh. , Actress, screenwriter and director Luciana Lagana ... this film together with her husband, Gregory Graham ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... 25, 2014 When head lice hits a ... a frenzy to get rid of it while keeping it ... Coral Gables now have the solution right in their neighborhood: ... location, Lice Troopers provides full spectrum head lice screening and ... area, including Sunset, Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest ...
Breaking Medicine News(10 mins):Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Black One-Shoulder Cocktail Dresses for 2015 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2
... Plan focuses on added benefits to improve care ... with chronic health conditions -, LITTLE ROCK, ... Medicare annual enrollment period which begins November 15th, ... 2009 Special Needs Plan,(SNP) offerings for chronically ill ...
... Points to Need for a Federal Office of Men,s ... national,phone and direct mail effort, was administered to the ... Washington, D.C.) and,the Governor,s Office, where appropriate. The survey ... Meeting in San,Diego on October 26th, 2008 and are ...
... of the National Organization for Rare Disorders ... Compassionate Allowances,initiative "an outstanding achievement" that will ... The initiative announced today will fast-track applications ... of 25 rare diseases and 25,cancers whose ...
... NANJING, China, Oct. 27 /Xinhua-PRNewswire/ -- Simcere ... manufacturer and supplier of branded generic,pharmaceuticals and ... market, announced today its participation in the ... conference will be,held at the Grand Hyatt ...
... led by UBC Psychiatry Prof. Weihong Song, who is also ... Disease at UBC, found that if Valproic Acid (VPA) is ... deficit is reversed. , The study, published in the Journal ... activity of an enzyme that produces a neurotoxic protein called ...
... Readers to Meaningful Coincidences, LOUISVILLE, Colo., Oct. ... Clearly Now: How Synchronicity Illuminates Our,Lives, has been ... in both Best New,Non-Fiction and Best New Age ... USABookNews.com, the premiere online magazine and review ...
Cached Medicine News:Health News:Care Improvement Plus Launches 2009 Benefits in Arkansas 2Health News:New State Public Health Department Survey Results Highlight Available Resources for Men and Women 2Health News:New Compassionate Allowances for Social Security Disability Represent 'Outstanding Achievement,' NORD Says 2Health News:Simcere Pharmaceutical Group to Participate in Goldman Sachs China Investment Frontier Conference 2008 2Health News:New Author Mary Soliel Honored as Two-time National Best Books 2008 Award Finalist 2
... The OcuLight family of infrared laser photocoagulators ... models. These diode lasers serve as a ... and applications, require no regular maintenance or ... their compact design. The OcuLight SLx is ...
... Using the latest in solid-state technology, ... green light at 532 nm. Patented ... delivery device options maximize versatility, compact ... and advanced design minimizes any routine ...
... Danker Laboratories manufacturers a ... orthokeratology lenses (also known ... "Corneal Reshaping" Lenses) according ... and demanding standards of ...
... The Euclid Systems Orthokeratology (oprifocon A) ... contact lenses used for orthokeratology, a ... The patient wears these lenses overnight ... During the day, nearsightedness is temporarily ...
Medicine Products: